Healthcare provider profile · identity verified

Michael Ku

Family Practice · KALAMAZOO, MI · NPI 1497862650

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	455	125
Amlodipine Besylate	Amlodipine Besylate	317	89
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	276	51
Metoprolol Succinate	Metoprolol Succinate	203	56
Levothyroxine Sodium	Levothyroxine Sodium	201	44
Lisinopril	Lisinopril	193	49
Omeprazole	Omeprazole	184	54
Gabapentin	Gabapentin	176	38
Olmesartan Medoxomil	Olmesartan Medoxomil	174	51
Tamsulosin Hcl	Tamsulosin Hcl	168	49
Hydrochlorothiazide	Hydrochlorothiazide	154	45
Alprazolam	Alprazolam	139	30
Losartan Potassium	Losartan Potassium	103	27
Furosemide	Furosemide	102	29
Albuterol Sulfate Hfa	Albuterol Sulfate	94	32
Tramadol Hcl	Tramadol Hcl	91	19
Metformin Hcl	Metformin Hcl	85	26
Rosuvastatin Calcium	Rosuvastatin Calcium	81	30
Pantoprazole Sodium	Pantoprazole Sodium	80	19
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	79	21
Simvastatin	Simvastatin	74	20
Eliquis	Apixaban	72	14
Trazodone Hcl	Trazodone Hcl	72	21
Duloxetine Hcl	Duloxetine Hcl	71	13
Metoprolol Tartrate	Metoprolol Tartrate	65	15
Zolpidem Tartrate	Zolpidem Tartrate	65	13
Meloxicam	Meloxicam	64	19
Fluoxetine Hcl	Fluoxetine Hcl	61	15
Allopurinol	Allopurinol	59	18
Lorazepam	Lorazepam	59	14
Fluticasone Propionate	Fluticasone Propionate	56	19
Potassium Chloride	Potassium Chloride	52	17
Bupropion Xl	Bupropion Hcl	50	11
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	49	16
Sertraline Hcl	Sertraline Hcl	49	13
Clonazepam	Clonazepam	48	suppressed
Pravastatin Sodium	Pravastatin Sodium	46	14
Famotidine	Famotidine	45	suppressed
Citalopram Hbr	Citalopram Hydrobromide	42	16
Lovastatin	Lovastatin	42	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	41	12
Montelukast Sodium	Montelukast Sodium	40	suppressed
Metformin Hcl Er	Metformin Hcl	39	suppressed
Ropinirole Hcl	Ropinirole Hcl	38	suppressed
Finasteride	Finasteride	37	11
Morphine Sulfate Er	Morphine Sulfate	36	suppressed
Enalapril Maleate	Enalapril Maleate	33	suppressed
Carvedilol	Carvedilol	31	suppressed
Prednisone	Prednisone	31	21
Betamethasone Valerate	Betamethasone Valerate	29	17
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	29	suppressed
Myrbetriq	Mirabegron	29	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	28	suppressed
Ibuprofen	Ibuprofen	28	14
Jardiance	Empagliflozin	28	12
Chlorthalidone	Chlorthalidone	27	suppressed
Diazepam	Diazepam	27	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	27	suppressed
Propranolol Hcl Er	Propranolol Hcl	26	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	25	17
Xarelto	Rivaroxaban	25	suppressed
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	24	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	24	suppressed
Valacyclovir	Valacyclovir Hcl	23	suppressed
Donepezil Hcl	Donepezil Hcl	22	suppressed
Januvia	Sitagliptin Phosphate	22	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	22	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	22	suppressed
Risperidone	Risperidone	22	suppressed
Clopidogrel	Clopidogrel Bisulfate	21	suppressed
Morphine Sulfate	Morphine Sulfate	21	suppressed
Ondansetron Hcl	Ondansetron Hcl	20	suppressed
Tizanidine Hcl	Tizanidine Hcl	20	suppressed
Bupropion Hcl Sr	Bupropion Hcl	19	suppressed
Celecoxib	Celecoxib	19	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	19	suppressed
Memantine Hcl	Memantine Hcl	18	suppressed
Methylphenidate Hcl	Methylphenidate Hcl	18	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	16	suppressed
Doxepin Hcl	Doxepin Hcl	16	suppressed
Estradiol	Estradiol	16	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	16	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	15	12
Atenolol	Atenolol	15	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	15	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	15	suppressed
Pregabalin	Pregabalin	15	suppressed
Dextroamphetamine-Amphet Er	Dextroamphetamine/Amphetamine	14	suppressed
Diphenoxylate-Atropine	Diphenoxylate Hcl/Atropine	14	suppressed
Lurasidone Hcl	Lurasidone Hcl	14	suppressed
Nystatin	Nystatin	14	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	14	suppressed
Alendronate Sodium	Alendronate Sodium	13	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	13	12
Diltiazem Hcl	Diltiazem Hcl	13	suppressed
Eszopiclone	Eszopiclone	13	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	13	suppressed
Loperamide	Loperamide Hcl	13	suppressed
Olanzapine	Olanzapine	13	suppressed
Spironolactone	Spironolactone	13	suppressed
Amlodipine-Atorvastatin	Amlodipine/Atorvastatin	12	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	12	suppressed
Methadone Hcl	Methadone Hcl	12	suppressed
Oxycodone Hcl	Oxycodone Hcl	12	suppressed
Ozempic	Semaglutide	12	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	12	suppressed
Topiramate	Topiramate	12	suppressed
Benazepril Hcl	Benazepril Hcl	11	suppressed
Cephalexin	Cephalexin	11	11
Diclofenac Sodium	Diclofenac Sodium	11	suppressed
Lansoprazole	Lansoprazole	11	suppressed
Mirtazapine	Mirtazapine	11	suppressed
Synthroid	Levothyroxine Sodium	11	suppressed
Torsemide	Torsemide	11	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error